Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

Imeglimin is an investigational first‐in‐class novel oral agent for the treatment of type 2 diabetes (T2D). Several pivotal phase III trials have been completed with evidence of statistically significant glucose lowering and a generally favourable safety and tolerability profile, including the lack...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Diabetes Obes Metab
Main Authors: Hallakou‐Bozec, Sophie, Vial, Guillaume, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Borel, Anne‐Laure, Fontaine, Eric, Moller, David E.
Format: Artigo
Sprog:Inglês
Udgivet: Blackwell Publishing Ltd 2020
Fag:
Review Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8049051/
https://ncbi.nlm.nih.gov/pubmed/33269554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14277
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker